Original contribution
Cancer of the urinary bladder category t2, t3, (NXM0) treated by interstitial radium implant: Second report

https://doi.org/10.1016/0360-3016(83)90064-0Get rights and content

Abstract

Three-hundred-twenty-eight patients with bladder cancer category T2NxM0 and 63 patients with category T3NxM0 have been treated by 3 times 3.5 Gy external irradiation followed by a radium implant. Overall 5- and 10-year survival in the T2 category are 56 % and 37 %. In the T3 category they are 39 % and 13 %, respectively. The intercurrent death (i.e. without evidence of bladder malignancy) corrected actuarial survival percentage in the T2 category is 75 % at 5 years and 69% at 10 years. The corresponding percentages in the T3 category are 62% and 59%. Prognosis is worsened by the following factors: more than 1 diagnostic transurethral resection, a pathological intravenous pyelography, non-papillary structure and poor degree of differentiation of the growth. Prognosis in category T3 , as compared with category T2 , is worse because of the prevalence of bad prognosticators in this T3 category. Therapeutic adaptation to these findings might improve prognosis in the future.

References (14)

There are more references available in the full text version of this article.

Cited by (58)

  • Brachytherapy after external beam radiotherapy and limited surgery preserves bladders for patients with solitary pT1-pT3 bladder tumors

    2012, Annals of Oncology
    Citation Excerpt :

    The tumor located in the bladder neck is a relative contra-indication for implantation as this area is not easily accessible for implant materials. This technique was first described by Breur et al. in 1956 and propagated by Van der Werf-Messing in the 1970s and 1980s [13–15]. About half of the radiation oncology departments in the Netherlands and a few centers in France and Belgium followed this technique [16–25].

  • Defining the Clinical Target Volume for Bladder Cancer Radiotherapy Treatment Planning

    2009, International Journal of Radiation Oncology Biology Physics
    Citation Excerpt :

    However, despite these recent advances, there still remain the ∼30% of patients who either fail to attain a complete response or subsequently develop a local relapse in the bladder (2). It is noteworthy that up to 95% of recurrences occur at the original site of disease (11). The International Commission on Radiation Units and Measurements (ICRU) Report 50 has provided a conceptual framework for 3D-CRT to ensure adequate coverage of the tumor with the prescription dose (12).

  • Radiotherapy for Bladder Cancer

    2007, Urology
    Citation Excerpt :

    Interstitial radiation, as an alternative to external-beam treatment, allows a high dose of radiation to be delivered focally to a small area of the bladder with relative sparing of surrounding normal tissues. It has been used to treat selected, otherwise well patients with solitary tumors that are <5 cm in diameter and preferably confined to the bladder wall (pT1 or pT2).21–26 The broadest experience to date with interstitial radiotherapy for bladder cancer, described by Rozan et al.,25 was based on the study of 205 patients treated at 8 radiotherapy centers in France.

  • Radiation therapy for muscle-invasive bladder cancer: Treatment planning and delivery

    2005, Clinical Oncology
    Citation Excerpt :

    Partial bladder treatments have been explored, fuelled by the knowledge that partial bladder-radiation tolerance is higher than the whole organ, with tolerance doses estimated at 80 Gy for two out of three of the bladders, and indeed higher for lesser volumes compared with 65 Gy for the whole organ [17,18]. Patterns of failure elucidated from the Dutch brachytherapy experience show that only 5–7% of patients develop recurrence at new sites within the bladder after brachytherapy implantation [19]. These data suggest that delivering treatment to the tumour (with margin) may be an alternative strategy.

View all citing articles on Scopus
View full text